Meeting
2022 ASCO Annual Meeting
Clinicopathologic and molecular features associated with response to anti-HER2 therapy in endometrial cancer.
Authors
Sherry Shen
Memorial Sloan Kettering Cancer Center, New York, NY
Sherry Shen , Weining Ma , Qin Zhou , Alexia Iasonos , Yanming Zhang , Dara S. Ross , Vicky Makker , Michael Herman Chui
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5584)
DOI
10.1200/JCO.2022.40.16_suppl.5584
Abstract #
5584
Poster Bd #
460
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
First Author: Dazhi Liu
Poster
2015 ASCO Annual Meeting
The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays.
First Author: Dara S. Ross
Poster
2023 ASCO Annual Meeting
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.
First Author: Ryul Kim
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
HER2 gene amplification and protein overexpression in uterine clear cell carcinoma and its implications in targeted immunotherapy.
First Author: Jain Zhou